About Ruth Foreman, MD

Dr. Ruth K. Foreman received her medical degree from the Harvard Medical School-Health Sciences and Technology Program.  Her doctorate was completed in Biology at the Massachusetts Institute of Technology in the laboratory of Dr. Rudolf Jaenisch. While in Dr. Jaenisch?s lab she studied epigenetic reprogramming, and was involved in some of the initial publications of the generation of induced pluripotent stem cells (iPS cells). The remainder of her thesis work focused on identifying non-viral alternatives, including small chemical compounds and proteins, to induce epigenetic reprogramming in differentiated cells. Dr. Foreman completed her clinical training in Anatomic Pathology at the Brigham and Women's Hospital, followed by a Dermatopathology Fellowship in the Harvard Combined Program. She is board certified in Anatomic Pathology and Dermatopathology and currently is a staff member in the Dermatopathology service. Dr. Foreman hopes to apply her background in molecular biology to her research interests in melanoma and inflammatory skin disorders.

Departments, Centers, & Programs:



Mass General Pathology
55 Fruit St.
Boston, MA 02114
Phone: 617-643-0800

Medical Education

  • MD, Harvard Medical School
  • Residency, Brigham and Women's Hospital
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Anatomic Pathology, American Board of Pathology
  • Dermatopathology, American Board of Pathology

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.



    1. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Lyssiotis CA, Foreman RK, Staerk J, Garcia M, Mathur D, Markoulaki S, Hanna J, Lairson LL, Charette BD, Bouchez LC, Bollong M, Kunick C, Brinker A, Cho CY, Schultz PG, Jaenisch R. Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):8912-7.
    2. Wnt signaling promotes reprogramming of somatic cells to pluripotency. Marson A, Foreman R, Chevalier B, Bilodeau S, Kahn M, Young RA, Jaenisch R. Cell Stem Cell. 2008 Aug 7;3(2):132-5.
    3. Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Brambrink T, Foreman R, Welstead GG, Lengner CJ, Wernig M, Suh H, Jaenisch R. Cell Stem Cell. 2008 Feb 7;2(2):151-9.
    4. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R. Nature. 2007 Jul 19;448(7151):318-24.
    5. Pan-Src family kinase inhibitors replace Sox2 during the direct reprogramming of somatic cells. Staerk J, Lyssiotis CA, Medeiro LA, Bollong M, Foreman RK, Zhu S, Garcia M, Gao Q, Bouchez LC, Lairson LL, Charette BD, Supekova L, Janes J, Brinker A, Cho CY, Jaenisch R, Schultz PG. Angew Chem Int Ed Engl. 2011 Jun 14;50(25):5734-6.
    6. Metastable pluripotent states in NOD-mouse-derived ESCs. Hanna J, Markoulaki S, Mitalipova M, Cheng AW, Cassady JP, Staerk J, Carey BW, Lengner CJ, Foreman R, Love J, Gao Q, Kim J, Jaenisch R. Cell Stem Cell. 2009 Jun 5;4(6):513-24. Erratum in: Cell Stem Cell. 2009 Jul 2;5(1):124.

Reviews: Comments and Ratings